Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME) With as few as two treatments per year, Susvimo may help people with DME maintain their vision Approval marks the second indication for Susvimo in addition to wet, or neovascular age-related macular [Read More]
Author: Dan Roberts
Current Technology for the Blind and Visually Impaired
Assistive technology for the visually impaired is available from low-tech optical and non-optical aids to electronics and digital technology. Visually impaired and blind individuals have a tremendous number of options to eyesight, depending upon their needs, goals, and financial situations. “Ethyl”, for example, likes to talk on her landline phone. When walking, she uses a [Read More]
Opportunity to Participate in Paid Geographic Atrophy Study
Global Perspectives is looking for people with advanced dry AMD (age-related macular degeneration), also known as geographic atrophy (GA). The purpose of this study is to understand patients’ views and preferences related to treatments for geographic atrophy including some that are in development. No treatments will be administered in this study, as only opinions are [Read More]
Genentech to Reintroduce Susvimo for People With Wet AMD
The FDA has approved updates to Susvimo, which will be available to U.S. retina specialists and patients with wet AMD in the coming weeks. Genentech announced today the reintroduction of Susvimo® (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people in the United States with wet, or neovascular, age-related [Read More]
Opportunity for People Affected by Geographic Atrophy
For persons with Geographic Atrophy due to Dry Age-related Macular Degeneration: Lagrippe Research is inviting three individuals diagnosed with Geographic Atrophy to participate in our upcoming discussion. We are also interested in speaking with family members / loved ones that assist and support people who have been diagnosed with GA. The research’s purpose is to [Read More]